These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19238515)

  • 1. Immunomodulation in the treatment of haematological malignancies.
    Cesco-Gaspere M; Morris E; Stauss HJ
    Clin Exp Med; 2009 Jun; 9(2):81-92. PubMed ID: 19238515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel immunotherapies for hematologic malignancies.
    Nelson MH; Paulos CM
    Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches in the immunotherapy of haematological malignancies.
    Costello RT; Rey J; Fauriat C; Gastaut JA; Olive D
    Eur J Haematol; 2003 May; 70(5):333-45. PubMed ID: 12694173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
    Ramsay AG
    Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
    Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
    Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in lymphoid disease.
    Eyre TA; Collins GP
    Br J Haematol; 2015 Aug; 170(3):291-304. PubMed ID: 25824455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapeutic approaches for hematologic malignancies.
    Caligiuri MA; Velardi A; Scheinberg DA; Borrello IM
    Hematology Am Soc Hematol Educ Program; 2004; ():337-53. PubMed ID: 15561691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in T-cell immunotherapy for haematological malignancies.
    Rouce RH; Sharma S; Huynh M; Heslop HE
    Br J Haematol; 2017 Mar; 176(5):688-704. PubMed ID: 27897332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in tumour immunotherapy.
    King J; Waxman J; Stauss H
    QJM; 2008 Sep; 101(9):675-83. PubMed ID: 18477644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells and their potential therapeutic role in haematological malignancy.
    Kaminski ER; Goddard RV; Prentice AG
    Leuk Lymphoma; 2003 Oct; 44(10):1657-66. PubMed ID: 14692516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of chimeric antigen receptor therapy for haematological malignancies.
    Maude S; Barrett DM
    Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular therapy to treat haematological and other malignancies: progress and pitfalls.
    Fromm PD; Gottlieb D; Bradstock KF; Hart DN
    Pathology; 2011 Oct; 43(6):605-15. PubMed ID: 21897329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotherapy of hematologic malignancies.
    Maloney DG
    Curr Opin Hematol; 1998 Jul; 5(4):237-43. PubMed ID: 9747629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!
    Grant ML; Bollard CM
    Blood Rev; 2018 May; 32(3):203-224. PubMed ID: 29198753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.